We have developed
lipid-polycation-
DNA (LPD) nanoparticles containing
DOTAP and targeted with
polyethylene glycol (PEG) tethered with anisamide (AA) to specifically deliver
siRNA to H460 human lung
carcinoma cells which express the
sigma receptor. A novel non-
glycerol based cationic
lipid which contains both a
guanidinium and a
lysine residue as the cationic headgroup, i.e. DSGLA, downregulated pERK more efficiently in H460 cells than
DOTAP. As demonstrated by using fluorescently labeled
siRNA, LPD-PEG-AA prepared with DSGLA efficiently delivered
siRNA to the cytoplasm of the H460 cells. Although the
siRNA delivered by LPD-PEG-AA containing either
DOTAP or DSGLA could effectively silence EGFR expression, a synergistic cell killing effect in promoting cellular apoptosis was only observed with DSGLA. The fluorescently labeled
siRNA was efficiently delivered into the cytoplasm of H460 xenograft
tumor by the LPD-PEG-AA containing either
DOTAP or DSGLA 4 h after
intravenous injection. Three daily
injections (0.6 mg/kg) of
siRNA formulated in the LPD-PEG-AA containing either
DOTAP or DSGLA could effectively silence the
epidermal growth factor receptor (EGFR) in the
tumor, but the formulation containing DSGLA could induce more cellular apoptosis. A significant improvement in
tumor growth inhibition was observed after dosing with LPD-PEG-AA containing DSGLA. Thus, DSGLA served as both a formulation component as well as a therapeutic agent which synergistically enhanced the activity of
siRNA.